A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30 mg risedronate in patients with Paget's disease.

Reid, I. R.; Devogelaer, Jean-Pierre; Miller, P.; Brown, J.; Fraser, W.; Hosking, D.; Diaz, C. M.; Stone, M.; Moniz, C.; Hooper, M.; Saidi, Y.; Su, G.; Pak, J.; Davis, J.; Fashola, T.; Krasnow, J.; Zelenakas, K.; Lyles, K.

A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30 mg risedronate in patients with Paget's disease.

Reid, I. R.

;

Devogelaer, Jean-Pierre

;

Miller, P.

;

Brown, J.

;

Lyles, K.

;et.al.

(2006) 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research — Location: Philadelphia (Pa) (15.September.2006)

Files

No attached file found for this publication.

Details

Authors

Reid, I. R.
Author
Devogelaer, Jean-PierreUCLouvain
Author
Miller, P.
Author
Brown, J.
Author
Lyles, K.
Author

Affiliations

Citations

APA
Chicago
FWB

Reid, I. R., Devogelaer, J.-P., Miller, P., Brown, J., Fraser, W., Hosking, D., Diaz, C. M., Stone, M., Moniz, C., Hooper, M., Saidi, Y., Su, G., Pak, J., Davis, J., Fashola, T., Krasnow, J., Zelenakas, K., & Lyles, K. (2006). A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30 mg risedronate in patients with Paget’s disease. Journal of Bone and Mineral Research, 21, S437-S437. https://hdl.handle.net/2078.5/139570 (Original work published 2006)